Contrast Media: Myeloma Protein Precipitates in Urography
Contrast Media: Myeloma Protein Precipitates in Urography
复制标题
造影剂：尿路造影中骨髓瘤蛋白沉淀
DOI：
--
复制
发表时间：
1966
期刊：
影响因子：
--
通讯作者：
Z. Zawadzki
中科院分区：
文献类型：
--
作者：
E. Lasser;J. Lang;Z. Zawadzki
1939年，Holman 1报道了一例多发性骨髓瘤患者，肾盂造影后出现肾功能衰竭。从本报告中尚不清楚肾盂造影是逆行型还是静脉型，并且直到对比研究后8至12天才发生肾功能衰竭。虽然该病例并不代表肾盂造影后多发性骨髓瘤肾衰的真正案例，但它提醒了随后的观察人员，这些手术对此类患者的潜在危害。Bartels等人在1954年记录了一例骨髓瘤患者静脉肾盂造影后出现急性肾衰竭的第一例。造影剂为碘吡雷（Diodrast）。自那时以来，又记录了14例病例。3-11所引用的15例中，13例行静脉肾盂造影，2例行逆行肾盂造影。进行了8项研究
IN 1939, Holman 1 described a patient with multiple myeloma in whom renal failure developed following pyelography. It is not clear from this report whether the pyelography was of the retrograde or intravenous type, and renal failure did not occur until 8 to 12 days after the contrast study. While this case does not represent a bona fide instance of renal failure in multiple myeloma consequent to pyelography, it nevertheless alerted subsequent observers to the potential hazards of these procedures in such patients. What appears to be the first genuine case of acute renal failure following intravenous pyelography in a patient with myelomatosis was recorded by Bartels et al 2 in 1954. The contrast material utilized here was iodopyracet (Diodrast). Since that time, 14 additional cases have been recorded. 3-11 Of the 15 cases cited, 13 had intravenous pyelography and 2 had retrograde pyelography. Eight studies were carried out with